Donor Cell-Derived Hematological Neoplasms after Hematopoietic Stem Cell Transplantation. a Systematic Review.
Biol Blood Marrow Transplant. 2018 Feb 02;:
Authors: Suárez-González J, Martínez-Laperche C, Kwon M, Balsalobre P, Carbonell D, Chicano M, Rodríguez-Macías G, Serrano D, Gayoso J, Díez-Martín JL, Buño I
Development of de novo hematological malignancies in donor cells following allogeneic stem cell transplantation provides a useful in vivo model to study the process of leukemogenesis. A systematic analysis of the cases reported in the literature was performed in order to identify risk factors and mechanisms involved in the pathogenesis of donor cell-derived hematological neoplasms (DCHN) and leukemogenic transformation. Relevant data were extracted from 137 cases. Cases of DCHN show a wide heterogeneity with regard to recipient/donor age, sex-mismatch and conditioning regimen. Some characteristics, such as the type of primary disease, the type of hematological malignancy of the DCHN and the stem cell source employed in the transplant procedure, differ from those expected. Mechanisms involved in the pathogenesis of DCHN are complex and several hypotheses have been proposed, such as pre-existing hematological neoplasms or pre-malignant clones in the donor, decreased immune surveillance and damage to bone marrow microenvironment in the recipient. Most likely several if not all of these mechanisms play a role in DCHN development. Novel approaches, such as next generation sequencing to study consecutive samples after allo-SCT in these patients, appear promising to decipher the mechanisms of leukemogenesis.
PMID: 29410295 [PubMed – as supplied by publisher]